CZT Cozart

RNS Number:0768C
Cozart PLC
14 August 2007

                           Cozart plc (the "Company")



               Disclosure of information required by AIM Rule 26



The Company today announces that the information required by Rule 26 of the AIM
Rules for Companies is available within the "Investor Relations" and "About the
Company" sections of the Company's website: www.cozartgroup.com





Enquiries:
Cozart plc:                                                  www.cozartgroup.com
Kate Wright, Company Secretary                          Tel: +44 (0)1235 861 483





Notes to editors - Cozart plc:

Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse. Cozart's products include laboratory based testing kits for the detection
of drugs in a variety of biological samples and the Cozart(R) RapiScan and
Cozart DDS systems, portable devices used for the on-site testing of drugs of
abuse in saliva (oral fluid) samples. In July 2004 Cozart floated on London's
AIM (trading symbol: CZT).   Cozart has wholly owned subsidiaries in Spain
(Spinreact SA based near Barcelona); Sweden (HL Scandinavia and Medib
Scandinavian), Italy (Cozart Italia) and the UK (Nemesis Scientific Limited).



Cozart supplies point of contact testing products, laboratory services and
forensic testing kits to the criminal justice (e.g. police forces, probation
services and prisons), medical (e.g. hospitals and drug dependency clinics) and
workplace markets (e.g. pre-employment, random and 'for cause' testing) both in
the UK and internationally.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCZZLFFDVBXBBF

Cozart (LSE:CZT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Cozart (LSE:CZT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024